Insulin receptor

• US 4,761,371 A
• Filed: 02/12/1985
• Issued: 08/02/1988
• Est. Priority Date: 02/12/1985
• Status: Expired due to Term

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Ramachandran, Janakiraman, Bell, John R., Ullrich, Axel
• Primary Examiner(s): Wiseman, Thomas G.
• Assistant Examiner(s): NOT, DEFINED
• Application Number:
  US06/700,776
• Time in Patent Office: 1,267 Days
• Field of Search: 435/68, 435/70, 435/91, 435/172.3, 435/235, 435/317, 435/253, 536/27, 935/32, 935/29, 935/54, 935/56, 935/60, 935/70, 935/72
• US Class Current: 435/69.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: C07K 14/72 for hormones for neuromediators C07K14/70571
• CPC Class Codes: C07K 16/20 from protozoa

Abstract

Insulin receptor is purified in accordance with this invention to a level sufficient to enable amino acid sequencing thereof. DNA encoding insulin receptor is provided, as well as methods for synthesizing insulin receptor or its mutant in heterologous host cells transformed with vectors containing such DNA. Knowledge of the amino acid sequence for insulin receptor enables the preparation of novel immunogenic conjugates and antibodies raised against such conjugates. Novel therapeutically useful forms of the insulin receptor and anti-receptor antibodies are described.

Claims

1. Isolated DNA encoding an insulin receptor or a fragment thereof encoding a biologically active insulin receptor polypeptide.

2. Isolated DNA which encodes a biologically active insulin receptor and which is capable of hybridizing with the DNA of FIG. 1B.

3. An oligonucleotide probe that is capable of hybridizing with DNA that encodes an insulin receptor and which is labelled with a detectable moiety.

4. A vector comprising DNA encoding an insulin receptor of a fragment thereof encoding a biologically active insulin receptor polypeptide.

5. The vector of claim 4 wherein the DNA is under the control of a viral promoter.

6. The vector of claim 4 additionally comprising DNA encoding a selection marker.

7. The vector of claim 6 wherein the marker is dihydrofolate reductase.

8. The vector of claim 4 wherein the DNA encodes a predetermined, site-specific mutant insulin receptor which is greater than about 40 percent homologous with the insulin receptor of FIG. 1b and which exhibits a biological activity in common with the insulin receptor of FIG. 1b.

9. The vector of claim 8 wherein the transmembrane sequence of the receptor is deleted.

10. A cell from a multicellular organism transformed with the vector of claim 4.

11. The cell of claim 10 which is a mammalian cell.

12. A method comprising culturing the cell of claim 10 in a nutrient medium, permitting the receptor to accumulate in the culture and recovering the receptor from the culture.

13. The method of claim 12 wherein the receptor is recovered from the culture medium.